Sai Life Sciences Ltd (SAILIFE) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue and Margin Outlook
Management consistently expects a medium-term revenue growth trajectory of 15% to 20% and EBITDA margins in the 28% to 30% range across the Sep'25, Dec'25, and Mar'26 quarters, with revenue projected to be weighted toward the second half of the fiscal year ending Mar'27 due to phased capacity additions, while accommodating temporary scale-up inefficiencies. [Status: Reaffirmed]
3 more themes on the ELITE plan.